Kymab Ltd Is A Clinical Stage Biopharmaceutical Company Based In Cambridgeunited Kingdomfounded In 2009It Specializes In The Discovery And Development Of Fully Human Monoclonal Antibody Therapeuticskymab Operates As A Subsidiary Of Sanofifollowing Its Acquisition In January 2021 For Approximately $1 1 Billionthe Company Employs Between 51 And 200 Staff And Has Raised Significant Funding From Notable Investorsincluding The Wellcome Trust And The Bill & Melinda Gates Foundation Kymab Utilizes Its Proprietary Kymousea C Platforma Transgenic Antibody System That Generates A Diverse Range Of Human Antibodiesthis Technology Supports The Rapid Identification Of High Affinity Monoclonal Antibodies For Therapeutic Applicationsparticularly In Immuno Oncology And Inflammationkymab Has Ten Active Discovery Programs And Collaborates With Pharmaceutical Companies And Academic Researchers Through Its Kymab Access Programwhich Offers Antibody Discovery Supportthe Company Is Well Positioned To Advance Its Clinical Candidates And Contribute To The Development Of Next Generation Biologics Within Sanofi S Research And Development Network
No conferences found for this company.
| Company Name | Kymab Ltd |
| Country |
United Kingdom
|
| Address | N/A |
| Telephone | N/A |
| N/A |
